Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multi-antigen loaded autologous dendritic cell vaccine (UCLA)
- Development stage
- Discontinued
- Lead developer
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
This autologous dendritic cell vaccine is an investigational cellular immunotherapy developed at the Jonsson Comprehensive Cancer Center (UCLA) for the treatment of advanced renal cell carcinoma (RCC). The vaccine is produced by isolating monocytes from a patient's blood via leukapheresis, which are then differentiated into dendritic cells ex vivo. These dendritic cells are 'loaded' or pulsed with multiple tumor-associated antigens (TAAs) derived from the patient's own tumor or specific recombinant proteins. Once matured and activated, the dendritic cells are re-administered to the patient to function as professional antigen-presenting cells. Their primary mechanism of action is to present these tumor antigens to the patient's T-lymphocytes, thereby inducing a systemic, targeted cytotoxic immune response against renal cell carcinoma cells.
- Other names
- autologous dendritic cell vaccine-Jonsson Comprehensive Cancer Center-renal cell carcinomamulti-antigen loaded dendritic cell vaccineUCLA multi-antigen DC vaccine
Beyond the preview
Go deeper on multi-antigen loaded autologous dendritic cell vaccine (UCLA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multi-antigen loaded autologous dendritic cell vaccine (UCLA).